JonesResearch assumed coverage of Precision BioSciences with a Buy rating and $30 price target. The firm views the company as an \"underappreciated gene editing story.\" The price target is based on PBGENE-HBV in hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, the analyst tells investors in a research note.
